Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile Oct. 9, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric pati

With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure. While awaiting a decision from the FDA on its novel non-opioid pain treatment, Viatris has agreed to buy Pacira BioSciences for $1.65 billion to accelerate its expansion into non-opioid pain therapy. Pacira sells Exparel and Zilretta, pain treatments that generated sales of $587 million and $121 million, respectively, in the s

October 8, 2026, Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded th

Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities. Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™ drug delivery platform. EPIPLANT™, the company's proprietary, episcleral sustained-release drug delivery platform is designed to address limitations of intraocular injections. A Phase 1/2a clinical study is scheduled for 2027

On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and ped

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 Oct. 09, 2026 -- HCW Biologics Inc. (the “Company” or “HCW

First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomize

Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an agile AI foundry for small-molecule drug discovery, today announced results from a research collaboration that has produced a validated-quality lead candidate directed at MSH3, a gene increasingly understood to drive the somatic repeat expansion that paces the progression of Huntington’s disease. The companies reached the milestone in a matter of weeks. Industry benchma

Sensible Biotechnologies, a biotechnology company developing cell-based manufacturing technologies for mRNA medicines, has raised $47 million to advance and scale its platform. The financing includes a Series A and up to $20 million in non-dilutive funding from Slovakia and the European Union. The company said the funding will support the development and scale-up of its VECTOR platform, expansion of its AI-enabled mRNA design and high-throughput screening capabilities, and development of clinica

SAN DIEGO---Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines for the treatment of fibrotic diseases with high unmet need, today announced that its Phase 2b WHISTLE-PF trial evaluating taladegib (ENV-101), an investigational Hedgehog signaling pathway inhibitor, met its primary endpoint and multiple key secondary endpoints in patients with idiopathic pulmonary fibrosis (IPF). Current standard-of-care therapies slow the decline of lung function but do